Dartmouth Health is the only health care system on the East Coast to be part of the newly launched Brain Health Navigator ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

The Davos Alzheimer’s Collaborative (DAC), a pioneering worldwide initiative seeking to cure Alzheimer’s disease and improve ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Activation of SIGMAR1 is expected to restore cellular homeostasis by inducing autophagy, which may slow neurodegeneration in patients with early AD.

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get Real-Time ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain ...